EUVIMEDEUVIMED entdecken
Crossref

Cardiovascular Safety of Atomoxetine and Methylphenidate in Patients With Attention-Deficit/Hyperactivity Disorder in Japan: A Self-Controlled Case Series Study

Yunlong Zheng iD, Toshiki Fukasawa iD, Fumitaka Yamaguchi, Masato Takeuchi, Koji Kawakami iD

Journal of Attention Disorders · 2024

DOI: 10.1177/10870547231214993 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Attention Disorders, 2024. Verfasst von Yunlong Zheng und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacoepidemiology, Graduate School of Medicine and Public Health, Kyoto University, Japan. Hauptthemen laut MEDLINE: Attention Deficit Disorder with Hyperactivity, Methylphenidate, Central Nervous System Stimulants, Stroke. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 44 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

To investigate the association between atomoxetine or methylphenidate use and arrhythmia, heart failure (HF), stroke, and myocardial infarction (MI) in attention-deficit/hyperactivity disorder (ADHD) patients mainly focused on the people of working age.

Methods

In a self-controlled case series study using a Japanese claims database, we identified events of arrhythmia, HF, stroke, and MI among 15,472 atomoxetine new users and 12,059 methylphenidate new users. Adjusted incidence rate ratios (aIRRs) of outcome events were estimated using multivariable conditional Poisson regression.

Results

An increased risk of arrhythmia was observed during the first 7 days after the initial atomoxetine exposure (aIRR 6.22, 95% CI [1.90, 20.35]) and in the subsequent exposure (3.23, [1.58, 6.64]). No association was found between methylphenidate exposure and arrhythmia, nor between atomoxetine or methylphenidate exposure and HF. The limited number of stroke and MI cases prevented thorough analysis.

Conclusions

Clinicians should consider monitoring for arrhythmia after patients initiating or re-initiating atomoxetine.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Attention Deficit Disorder with HyperactivityMethylphenidateCentral Nervous System StimulantsStrokeHumansAtomoxetine HydrochlorideJapanArrhythmias, CardiacAdrenergic Uptake Inhibitors

Stichwörter der Autor:innen

ADHDAtomoxetineCardiovascular eventsMethylphenidateSelfcontrolled case series study

Substanzen

MethylphenidateAtomoxetine HydrochlorideCentral Nervous System StimulantsAdrenergic Uptake Inhibitors

Autor:innen und Institutionen

  • Department of Pharmacoepidemiology, Graduate School of Medicine and Public Health, Kyoto University, Japan.
  • Department of Digital Health and Epidemiology, Graduate School of Medicine and Public Health, Kyoto University, Japan.

ORCID-Profile: Yunlong Zheng, Toshiki Fukasawa, Koji Kawakami

Zitieren

APA

Zheng, Y., Fukasawa, T., Yamaguchi, F., Takeuchi, M., & Kawakami, K. (2024). Cardiovascular Safety of Atomoxetine and Methylphenidate in Patients With Attention-Deficit/Hyperactivity Disorder in Japan: A Self-Controlled Case Series Study. Journal of Attention Disorders. https://doi.org/10.1177/10870547231214993

Vancouver

Zheng Y, Fukasawa T, Yamaguchi F, Takeuchi M, Kawakami K. Cardiovascular Safety of Atomoxetine and Methylphenidate in Patients With Attention-Deficit/Hyperactivity Disorder in Japan: A Self-Controlled Case Series Study. Journal of Attention Disorders. 2024. doi:10.1177/10870547231214993

BibTeX
@article{Zheng2024,
  author = {Zheng, Yunlong and Fukasawa, Toshiki and Yamaguchi, Fumitaka and Takeuchi, Masato and Kawakami, Koji},
  title = {Cardiovascular Safety of Atomoxetine and Methylphenidate in Patients With Attention-Deficit/Hyperactivity Disorder in Japan: A Self-Controlled Case Series Study},
  journal = {Journal of Attention Disorders},
  year = {2024},
  doi = {10.1177/10870547231214993}
}
Kostenlos starten →